These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of renal impairment on the pharmacokinetics of cibenzoline. Massarella JW; Khoo KC; Aogaichi K; Di Persio D; Smith M; Kluger J; Chow MS Clin Pharmacol Ther; 1988 Mar; 43(3):317-23. PubMed ID: 3345622 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cibenzoline in patients with renal impairment. Canal M; Flouvat B; Aubert P; Guedon J; Prinseau J; Baglin A J Clin Pharmacol; 1985 Apr; 25(3):197-203. PubMed ID: 3998200 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study. Wasty N; Saksena S; Barr MJ Am Heart J; 1985 Dec; 110(6):1181-8. PubMed ID: 4072875 [TBL] [Abstract][Full Text] [Related]
7. Heart failure elevates serum levels of cibenzoline in arrhythmic patients. Kotake T; Takada M; Komamura K; Kamakura S; Miyatake K; Kitakaze M; Morishita H Circ J; 2006 May; 70(5):588-92. PubMed ID: 16636495 [TBL] [Abstract][Full Text] [Related]
8. Effects on rabbit nodal, atrial, ventricular and Purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia. Millar JS; Vaughan Williams EM Br J Pharmacol; 1982 Mar; 75(3):469-78. PubMed ID: 7066601 [TBL] [Abstract][Full Text] [Related]
9. Determination of cibenzoline in plasma and urine by high-performance liquid chromatography. Hackman MR; Lee TL; Brooks MA J Chromatogr; 1983 Apr; 273(2):347-56. PubMed ID: 6863449 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline. Canal M; Flouvat B; Tremblay D; Dufour A Eur J Clin Pharmacol; 1983; 24(4):509-15. PubMed ID: 6861865 [TBL] [Abstract][Full Text] [Related]